Navigation Links
Researchers use 'trickery' to create immune response against melanoma

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

Nucleic acid ligands (referred to as aptamers) are short DNA or RNA fragments that can bind to target antigens with high specificity and affinity; analogous to monoclonal antibodies. In the field of cancer nanotechnology, aptamers have the potential to act as targeting molecules - directing the delivery of nanoparticles to tumour-antigens, present on the surface of cancer cells. In general terms, therapeutic nanoparticles (~50 ?~250 nanometer) are specially designed delivery vehicles that can encapsulate a drug within them and release the drug in a pre-determined and regulated manner which can vary from a sudden release to a slow release over a period of several years. Using prostate cancer as a model disease, proof of concept nanoscale targeted drug delivery vehicles were developed (1 nanometer = 0.000000001 meter), which can target prostate cancer cells with high specificity and efficiency. Once bound to prostate cancer cells, the nanoparticle/aptamer bioconjugates were internalised making it possible for their cytotoxic payload to get released directly inside the cancer cells. The combination of targeted delivery and controlled release of drugs at the site of cancer will likely result in "smart therapeutics" that are more effective, yet safer than what is available today.

As the initial step, researchers synthesised nanoparticles for controlled drug release made from a biocompatible and biodegradable PLA polymer system and encapsulated a fluorescently labeled model drug within them, in order to visualise nanoparticle uptake into target cells. The nanoparticles in question were designed for attachment to aptamers so that the binding properties of aptamers for targeti
'"/>

Source:University of Pittsburgh Medical Center


Page: 1 2 3 4

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/4/2009)...eavy traffic corridors in the cities of Long Beach...roportion of preventable childhood asthma, and the...n the disease has likely been underestimated, acco... California (USC). , The study, which appears i...blic Health , estimated that nine percent of all c...
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
(Date:11/4/2009)...he University of Oklahoma at Norman has received m...funding agencies as part of the federal stimulus p...ng received by OU researchers to $23 million. Thi...search ranging from archaeology to weather. , "T...atic approach to matching areasof scholarly excell...
Breaking Biology News(10 mins):USC study finds big air pollution impacts on local communities 2Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics 51599 1New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics 51599 2Inspiration Biopharmaceuticals Presents Safety Data on IB1001 a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Soci 13015 1Inspiration Biopharmaceuticals Presents Safety Data on IB1001 a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Soci 13015 2JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 51594 1JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 51594 2
...a Tech researchers in computer science and biology...X, to create models and algorithms that make it po... leading to cell division. They have demonstrated ...orithms provide powerful tools for studying the co...ologist John Tyson, who studies the cell cycle, is...
...ity of Newcastle researcher Kathryn Skelding, fund...ralytics Ltd, has been working on a new treatment ...improvement on conventional chemotherapy and radia...ells. , "In theory, the virus is able to selective...er cells, including breast cancers, whilst leaving...
...ent, chronic pain has risen dramatically among ful...ers today opt to go to their jobs rather than call...sm ?a negative impact on work despite being physic...y, are from a 2006 national survey conducted by Ha....painandwork.com ), sponsored by PriCaraƔ, Unit of...
Other Biology News:Virginia Tech's System X supercomputer provides super tool for simulation of cell division 2Virginia Tech's System X supercomputer provides super tool for simulation of cell division 3Common cold virus may kill breast cancer cells 2Chronic pain up almost 40 percent among US workers in past decade 2
(Date:11/6/2009)...ONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Bio...it has re-filed the Form 52-109F1 Certification of...tive Officer and James Long, the Chief Financial O...y 12, 2009 in connection with the annual audited f...0, 2008. ,, The Company initially filed the ann...
(Date:11/6/2009)...ORA, Ontario, Nov. 6 Hel... HXBPF) today announced that John Docherty, presid...erriman Curhan Ford,s 6th annual Investor Summit o...l in New York City. Mr. Docherty will provide an ...ent programs L-DOS47 and Topical Interferon Alpha-...
(Date:11/6/2009)... VIENNA, Austria, November 6 EUCOD...manufacturing, and marketing enzymes for the,chemi...nto a research,agreement with Bio Sidus, the leadi..., The agreement gives EUCODIS Bioscience exc...est - to Bio Sidus, proprietary collection of,psyc...
(Date:11/6/2009)...ING VALLEY, Calif., Nov. 6 Calbiot... a Small Business Innovative Research (SBIR) Phase...Material command. Under terms of the agreement, Ca...SRs) for the diagnosis of Dengue virus. ,, D...resents a major threat to military forces deployed...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
...tober 27 Stallergenes has,just obtained authoriza...ng,a phase III clinical trial in the United States...gic rhinoconjunctivitis to grass pollens in adults...in 450 American patients,during the 2009 pollen se...e of the product in adults and to support the appl...
...Oct. 27 Dr. Annie De Groot, CEO of,EpiVax, is the...gs about,the activation of natural regulatory T ce... or "Tregitopes." These findings were published in... medical journal published by,the American Society...chel Caspi of the National Institutes,of Health (N...
... Edmontonians magazine is partnering with ...chnology community and its companies and prove how...ct businesses. , Edmonton...onthly business publication serving the Capital Re...t, Innovation, Ingenuity project with the goal of...
Other Biology Technology:Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 2Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009 3Publication on 'Tregitopes' in Blood Journal of October 2008 2Edmonton's Technology Community: Using Social Media to Raise Awareness 2
Rabbit Anti-ZNF261 Polyclonal Antibody, Unconjugated from Abcam
Psp1406 I from Takara Mirus Bio
Mouse Anti-Integrin alpha M Monoclonal Antibody, Unconjugated, Clone ICRF 44 from Novus Biologicals
Rabbit Anti-CKB, N-Terminus Polyclonal Antibody, Unconjugated from Abgent
Biology Products: